安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- CATNON Final Results in IDH-Mutant Grade 3 Astrocytoma
In a disease where median survival can extend beyond a decade, these results provide a stable foundation for current standards and a benchmark against which emerging strategies—particularly IDH inhibitors in higher-grade disease—will need to compete Read the full article
- Oncolytic Virotherapy for Relapsed, IDH-Mutant, Grade 3 Astrocytoma: A . . .
Based on this rationale, we present the treatment course and remarkable response to IO-OV of a 37-year-old patient with relapsed astrocytoma and multifocal MRI lesions who presented with severe clinical deterioration
- Clinical trial tests a newer, targeted therapy for IDH mutant astrocytoma
People diagnosed with IDH-mutant, grade 3 astrocytoma usually receive surgery, followed by radiation and temozolomide, an oral chemotherapy pill Temozolomide works by damaging the DNA of
- Treatment and prognosis of IDH-mutant astrocytomas in adults
Across all grades, the presence of an IDH mutation identifies a group of tumors with a more prolonged natural history and favorable prognosis than that of IDH-wildtype tumors
- Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse . . . - ASTRO
This guideline addresses the management of adult patients with IDH-mutant grade 2 and grade 3 diffuse glioma as defined by WHO 2021 classification
- Current Considerations in the Treatment of Grade 3 Gliomas
Treatment consists of maximal safe surgery, followed by radiation therapy (RT) and alkylating agent–based chemotherapy Based on the updated CATNON result, RT followed by temozolomide improves outcome in patients with non-codeleted grade 3 IDHmt astrocytoma
- Breakthrough Trial Shows Promising Therapy for Aggressive Brain Cancer
Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an aggressive form of brain cancer, live longer
- Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults . . .
Given the available data, the consensus of the Expert Panel was that the preponderance of the evidence favors RT and chemotherapy for patients with IDH-mutant, 1p19q non-codeleted diffuse astrocytoma (grade 2, low-grade glioma and anaplastic astrocytoma [grade 3])
|
|
|